{"analyses":[{"ciLowerLimit":"0.4255","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.2698","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2698","paramType":"Odds Ratio (OR)","paramValue":"0.7350","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3"},{"groupId":"OG001","value":"16.3"},{"groupId":"OG002","value":"21.0"}]}],"title":"Under-treated (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5"},{"groupId":"OG001","value":"83.7"},{"groupId":"OG002","value":"79.0"}]}],"title":"Correctly or Over-treated (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1444"},{"groupId":"OG001","value":"1115"},{"groupId":"OG002","value":"329"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\nThe CRS quantifies whether the decision to initiate EP2006 as either primary or secondary prophylaxis is consistent with the EORTC guideline (2010) recommendation based upon the patient's chemotherapy toxicity (\\<10%, 10-20% or \\>20% risk of FN) and the PRS. There are three possible results: under-treated, correctly treated, over-treated","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: All Patients"},{"description":"Cancer patients (Solid tumor) treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Solid Tumor"},{"description":"Cancer patients (Hematological tumor) treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG002","title":"EP2006: Hematological Tumor"}],"paramType":"NUMBER","populationDescription":"Evaluable sample: total and by tumor type","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Percentage of Patients With Each Chemotherapy Risk Score (CRS) Result by Tumor Type","type":"PRIMARY","unitOfMeasure":"percentage of patients"}